Abbott Adds Patient Monitoring Strength With St. Jude Buy

While Abbott's purchase of St. Jude Medical will notably expand Abbott's reach in heart devices, it also places Abbott into patient monitoring. Patient monitoring is one of the fastest growing device areas, with double-digit growth expected the next 5 years, according to Kalorama Information's report, Advanced Remote Patient Monitoring  Abbott Laboratories agreed to acquire St. Jude Medical Inc.

Early Implications of the Zika Virus for the U.S. Diagnostics Market

In addition to its blog posts regarding infectious disease threats, Kalorama Information offers a comprehensive market research report for global infectious disease testing.

Since the last blog entry regarding Zika virus diagnostics, the U.S. Centers for Disease Control and Prevention (CDC) has issued emergency use authorizations (EUA) for a Zika IgM Antibody Capture ELISA (MAC-ELISA) kit and real-time reverse transcriptase PCR (RT-PCR) kit. Controls and kit reagents are available through the CDC, but their distribution is limited to qualified, PHEP-funded state and local public health laboratories. Mosquito-borne transmission of the Zika virus in the continental United States is likely to first occur this year through the disease’s principal vector, A. aegypti mosquitoes, present in up to 25 U.S. states.

World Vaccine Market Nears $28 Billion

Revenues earned by manufacturers of vaccines worldwide reached $27.6 billion in 2015, up from $24.7 billion in 2014 as sales in all segments expanded.   This according to our most recent study Kalorama Information’s report: Vaccines 2016:World Market Analysis   Kalorama finds that sales of pediatric vaccines constitute the larger market according to the report, accounting for 57.6% of the total vaccines market..

After Allergan Merger Halt, Vaccines a Focus for Pfizer

New U.S. Treasury regulation has dissuaded Pfizer from its planned merger with Ireland-based Allergan. The two companies agreed on Tuesday to terminate the deal. The tax inversion move would have benefited Pfizer’s profitability and reintroduced the company to the dermatologics market. Pfizer will now consider business divestitures in order to boost its profits. Pfizer previously spun-off its animal health business in 2013, which now operates as the veterinary pharmaceuticals and diagnostics company Zoetis.

Quest and DiaSorin to Focus on Key Markets Following Acquisition Deal

This blog post reviews aspects of DiaSorin’s acquisition of Focus Diagnostics from Quest Diagnostics that are relevant to markets reviewed in Kalorama Information reports The World Market for Infectious Disease Diagnostic Tests, Clinical Laboratory Services Market, and Mergers and Acquisitions in the IVD Market.

At the end of March, Quest Diagnostics and DiaSorin S.p.A. announced the latter’s acquisition of Quest subsidiary Focus Diagnostics, Inc. for $300 million. The deal assists Quest Diagnostics’ business streamlining and DiaSorin’s market expansion as they further commit to respective key strategic markets in “diagnostic information services” and infectious disease diagnostics. The deal continues internal trends for both companies: divestiture of non-core business units by Quest Diagnostics and DiaSorin’s market diversification outside of its traditional core non-infectious lab immunoassay products. Higher growth opportunities await the companies following Quest Diagnostics’ refinement of its business development model and DiaSorin’s bolt-on acquisition.


Subscribe to Kalorama Information Home RSS